Definium Therapeutics jumps after positive Phase 3 depression trial results

Definium Therapeutics (DFTX) is up 45.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied to Definium’s June 22, 2026 announcement of positive topline results from its Phase 3 Emerge study of DT120 ODT in major depressive disorder. Investors likely reacted to the combination of strong efficacy, durable symptom improvement, and a tolerability profile that management framed as supportive of a potential future regulatory submission.

Details:

Definium said Emerge met its primary endpoint and all key secondary efficacy endpoints in major depressive disorder.

The company reported an 8.1-point placebo-adjusted improvement on the MADRS depression scale at Week 6, plus a 7.3-point placebo-adjusted improvement at Week 12, suggesting durability after a single dose.

Management said DT120 ODT was generally well tolerated, with no serious adverse events and no suicidality signal identified in the topline release.

Earlier company materials had highlighted Emerge as a major late-second-quarter 2026 catalyst, and Definium previously said it had cash, cash equivalents, and investments expected to fund operations into 2028.

Sources:

Definium Therapeutics, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DFTX Insider Trading Activity

$DFTX insiders have traded $DFTX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $DFTX stock by insiders over the last 6 months:

ROBERT BARROW (Chief Executive Officer) sold 24,431 shares for an estimated $451,240
MARK SULLIVAN (Chief Legal Officer) sold 10,702 shares for an estimated $197,665
DANIEL KARLIN (Chief Medical Officer) sold 8,018 shares for an estimated $148,092

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$DFTX Hedge Fund Activity

We have seen 202 institutional investors add shares of $DFTX stock to their portfolio, and 5 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 8,480,230 shares (+inf%) to their portfolio in Q1 2026, for an estimated $156,163,435
AVORO CAPITAL ADVISORS LLC added 5,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $92,075,000
DEEP TRACK CAPITAL, LP added 3,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $55,245,000
GEODE CAPITAL MANAGEMENT, LLC added 2,495,399 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,952,772
STATE STREET CORP added 2,471,873 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,519,541
OCTAGON CAPITAL ADVISORS LP added 2,440,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $44,932,600
COMMODORE CAPITAL LP added 2,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $36,830,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DFTX Analyst Ratings

Wall Street analysts have issued reports on $DFTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 01/30/2026

To track analyst ratings and price targets for $DFTX, check out Quiver Quantitative's $DFTX forecast page.

$DFTX Price Targets

Multiple analysts have issued price targets for $DFTX recently. We have seen 8 analysts offer price targets for $DFTX in the last 6 months, with a median target of $33.0.

Here are some recent targets:

Sumant Kulkarni from Canaccord Genuity set a target price of $38.0 on 06/16/2026
David Amsellem from Piper Sandler set a target price of $48.0 on 05/08/2026
Marc Goodman from Leerink Partners set a target price of $30.0 on 04/22/2026
Paul Matteis from Stifel set a target price of $30.0 on 04/17/2026
Patrick R. Trucchio from HC Wainwright & Co. set a target price of $70.0 on 03/02/2026
Rudy Li from Wolfe Research set a target price of $25.0 on 02/24/2026
Andrew Tsai from Jefferies set a target price of $30.0 on 01/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.